Akebia Therapeutics Set for Breakout Amid Strong Clinical Outcomes
AI Prediction of Akebia Therapeutics (AKBA)
Akebia Therapeutics is poised for significant stock movement due to recent positive developments and upcoming catalysts. The company's robust pipeline, particularly Vafseo's performance and potential FDA approvals, could drive investor interest and stock valuation in the near term.
AKBA Report Information
Prediction Date2025-07-03
Close @ Prediction$3.62
Mkt Cap982m
IPO DateN/a
AI-derived Information
Recent News for AKBA
- Aug 6, 1:10 am — Akebia Therapeutics Inc (AKBA) (Q2 2026) Earnings Call Highlights: Vafseo Surges 60% as VOICE ... (GuruFocus.com)
- Aug 5, 5:04 pm — Akebia Therapeutics: Q2 Earnings Snapshot (Associated Press)
- Aug 5, 4:05 pm — Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights (GlobeNewswire RSS)
- Aug 3, 4:05 pm — Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire RSS)
- Aug 3, 8:00 am — Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases (GlobeNewswire RSS)
- Jul 29, 8:00 am — Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights (GlobeNewswire RSS)
- Jul 2, 4:05 pm — Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire RSS)
- Jun 30, 8:00 am — U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA (GlobeNewswire RSS)
- Jun 10, 8:00 am — Akebia Therapeutics Strengthens Vafseo® (vadadustat) Patent Portfolio (GlobeNewswire RSS)
- Jun 1, 4:05 pm — Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire RSS)
- May 28, 8:00 am — Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference (GlobeNewswire RSS)
- May 7, 7:10 am — Akebia Therapeutics: Q1 Earnings Snapshot (Associated Press)
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.